 It is a humanized monoclonal antibody functioning as a terminal complement inhibitor.It has been developed, manufactured, and marketed by Alexion Pharmaceuticals, which had patent exclusivity until 2017.Alexion started selling eculizumab in 2007 making $295 million in 2008 with its stock price rising 130% in 2010.